Home/Pipeline/EKZ-102

EKZ-102

Amyotrophic Lateral Sclerosis (ALS)

PreclinicalActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Preclinical

Status

Active

Company

Eikonizo Therapeutics

About Eikonizo Therapeutics

Eikonizo Therapeutics is a private, preclinical-stage biotech focused on selective HDAC6 inhibitors. Its lead CNS candidate, EKZ-102, is in IND-enabling studies for ALS, with plans to expand to other neurodegenerative diseases. The company is also developing peripheral HDAC6 inhibitors for cardiorenal indications like ADPKD and diabetic nephropathy, leveraging a platform designed for high selectivity and CNS penetrance to minimize side effects.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Cardiorenal Diseases

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active